📊 ADGM Key Takeaways
Is Adagio Medical Holdings, Inc. (ADGM) a Good Investment?
Adagio Medical is in severe financial distress with complete revenue collapse ($0), substantial operating losses (-$5.2M), and excessive leverage (4.0x debt-to-equity), indicating a non-viable business. With negative operating cash flow (-$4.1M) and limited cash runway, the company faces existential viability concerns in a capital-intensive medical devices sector requiring sustained R&D investment.
Adagio Medical Holdings appears fundamentally very weak based on the latest SEC data: it generated no revenue while posting a $21.78M net loss and burning $15.74M of free cash flow. The balance sheet is stressed, with negative equity, sub-1.0 liquidity ratios, and only $4.67M of cash against ongoing operating losses, which points to high financing and execution risk.
Adagio Medical Holdings, Inc. Key Strengths (ADGM)
- Maintains adequate short-term liquidity (1.85x current ratio, 1.66x quick ratio)
- Holds $12.9M cash providing near-term operational runway
- Company remains listed on Nasdaq and has not filed for bankruptcy (as of filing date)
- Total assets of $31.55M provide some operating base to support development and commercialization efforts
- Capital expenditure is relatively modest at $865K, so cash usage is not being driven by heavy fixed-asset expansion
- Recent SEC data as of 2025-09-30 gives timely visibility into the company's financial position
ADGM Stock Risks: Adagio Medical Holdings, Inc. Investment Risks
- Complete revenue collapse (100% YoY decline to $0) with no visible recovery path or commercialization timeline
- Highly leveraged balance sheet (4.0x debt-to-equity) with $22.9M long-term debt against $5.7M stockholders equity creating default risk
- Negative operating cash flow (-$4.1M annual burn) with approximately 3-year maximum cash runway at current burn rate
- Unsustainable losses (-$5.2M operating, -$7.0M net) requiring immediate revenue resumption for survival
- Medical devices sector requires substantial R&D and regulatory approval—company lacks revenue to fund either
- Minimal insider trading activity suggests low management confidence in recovery
- Zero revenue indicates the business has not yet demonstrated commercial traction or operating leverage
- Negative stockholders' equity and current ratio of 0.84x signal a fragile financial position
- Free cash flow burn of $15.74M versus $4.67M in cash implies limited runway without additional capital
Key Metrics to Watch
- Revenue recognition and resumption of commercial operations
- Monthly cash burn rate and cash position depletion timeline
- Debt refinancing, restructuring, or covenant violation announcements
- Form 8-K filings for material events or strategic pivots
- Clinical trial status or regulatory pathway updates in SEC filings
- Quarterly revenue generation and commercialization progress
- Cash balance relative to operating cash burn
Adagio Medical Holdings, Inc. (ADGM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Adagio Medical Holdings, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ADGM Profit Margin, ROE & Profitability Analysis
ADGM vs Healthcare Sector: How Adagio Medical Holdings, Inc. Compares
How Adagio Medical Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Adagio Medical Holdings, Inc. Stock Overvalued? ADGM Valuation Analysis 2026
Based on fundamental analysis, Adagio Medical Holdings, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Adagio Medical Holdings, Inc. Balance Sheet: ADGM Debt, Cash & Liquidity
ADGM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Adagio Medical Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-26.08 indicates the company is currently unprofitable.
ADGM Revenue Growth, EPS Growth & YoY Performance
ADGM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$7.0M | $-0.31 |
| Q3 2025 | N/A | $3.6M | $0.02 |
| Q2 2025 | $254.0K | -$3.9M | $-0.35 |
| Q1 2025 | $26.0K | -$7.7M | $-0.51 |
| Q3 2024 | $41.0K | $3.6M | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Adagio Medical Holdings, Inc. Dividends, Buybacks & Capital Allocation
ADGM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Adagio Medical Holdings, Inc. (CIK: 0002006986)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADGM
What is the AI rating for ADGM?
Adagio Medical Holdings, Inc. (ADGM) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADGM's key strengths?
Claude: Maintains adequate short-term liquidity (1.85x current ratio, 1.66x quick ratio). Holds $12.9M cash providing near-term operational runway. ChatGPT: Total assets of $31.55M provide some operating base to support development and commercialization efforts. Capital expenditure is relatively modest at $865K, so cash usage is not being driven by heavy fixed-asset expansion.
What are the risks of investing in ADGM?
Claude: Complete revenue collapse (100% YoY decline to $0) with no visible recovery path or commercialization timeline. Highly leveraged balance sheet (4.0x debt-to-equity) with $22.9M long-term debt against $5.7M stockholders equity creating default risk. ChatGPT: Zero revenue indicates the business has not yet demonstrated commercial traction or operating leverage. Negative stockholders' equity and current ratio of 0.84x signal a fragile financial position.
What is ADGM's revenue and growth?
Adagio Medical Holdings, Inc. reported revenue of $0.0.
Does ADGM pay dividends?
Adagio Medical Holdings, Inc. does not currently pay dividends.
Where can I find ADGM SEC filings?
Official SEC filings for Adagio Medical Holdings, Inc. (CIK: 0002006986) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADGM's EPS?
Adagio Medical Holdings, Inc. has a diluted EPS of $-0.31.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ADGM's fundamental grade?
Based on our AI fundamental analysis in June 2026, Adagio Medical Holdings, Inc. has a D grade with 94% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ADGM stock overvalued or undervalued?
Valuation metrics for ADGM: ROE of -122.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ADGM's AI grade for 2026?
Our dual AI analysis gives Adagio Medical Holdings, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADGM's free cash flow?
Adagio Medical Holdings, Inc.'s operating cash flow is $-4.1M, with capital expenditures of $2.0K.
How does ADGM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -122.2% (avg: 15%), current ratio 1.85 (avg: 2).
Is Adagio Medical Holdings, Inc. carrying too much debt?
ADGM has a debt-to-equity ratio of 4.00x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.85 suggests adequate short-term liquidity.